During the RBDCOV partners’ meeting the first RBDCOV Scientific Coffee, a lively and thought-provoking debate, was held at the iconic Ateneu of Barcelona. The discussion focused on the importance of inclusivity in clinical trials, with particular attention to immunocompromised individuals and pediatric populations.
The Science Café welcomed attendees from various organizations, fostering a dynamic exchange of ideas. Expert panelists included:
- Dr. Beatriz Mothe Pujadas, Principal Investigator of the HH-4 clinical trial for the COVID-19 vaccine at IrsiCaixa,
- Dr. Pere Soler-Palacín, Head of the Pediatric Infectious Diseases and Immunodeficiencies Unit at Vall d’Hebron Children’s Hospital,
- Joan Tallada, member of the RBDCOV Community Advisory Board (CAP) and a contributor to the European AIDS Treatment Group,
- Dr. Petra Wülfroth, Chief Scientific Officer (CSO) at F4 Pharma and consortium partner in the Horizon Europe project COVend.
If you missed this impactful session, you can watch it now on the project’s YouTube channel, available in English and the original Spanish version!
The discussion delved into the challenges and barriers to inclusion in clinical trials, emphasizing their critical impact on public health and treatment effectiveness.
At RBDCOV, we are committed to driving more inclusive and effective clinical research. Stay tuned for more updates as we continue making strides toward this shared goal!
Need help for your EU-funded projects? Contact us at: [email protected]
